AIM
NYSEAIM ImmunoTech Inc.
Basic Materials · Biological Products, (No Diagnostic Substances)
Research view
Fundamentals · SEC EDGAR · FY 2025-12-31
Revenue & Earnings — fiscal year
🔒 price chart needs market-data feed$135,000
2021
$141,000
2022
$202,000
2023
$170,000
2024
$88,000
2025
Snapshot
SEC EDGAR · FY 2025-12-31Revenue$88,000
Net Income$-14.0M
Gross Profit—
Oper Income$-11.7M
EPS (dil)$-8.62
Rev/sh$0.01
FCF/sh$-0.75
Book/sh$-0.67
Gross M—
Oper M-13254.5%
Profit M-15861.4%
FCF M-12471.6%
ROE142.7%
ROA-241.4%
ROIC—
R&D/Rev4459.1%
Rev Y/Y-48.2%
Rev 3Y CAGR-14.5%
EPS Y/Y72.1%
EPS 3Y CAGR—
FCF 3Y CAGR—
Payout—
Div/sh—
Shs Chg Y/Y+189%
Current Ratio0.53
Quick Ratio—
Debt/Eq-0.82
Int Coverage-14.4×
Net Debt$5.0M
Total Debt$8.0M
Cash & Eq$3.0M
Total Assets$5.8M
Oper CF$-11.0M
Capex$18,000
Free CF$-11.0M
Buybacks—
Equity$-9.8M
Liabilities$15.6M
Shs Outstand0.01B
SectorBasic Materials
🔒 P/E—
🔒 Fwd P/E—
🔒 P/S—
🔒 P/B—
🔒 Market Cap—
🔒 Div Yield—
🔒 52W Range—
🔒 Beta—
40+ fundamentals — free from SEC EDGAR (public domain). Only the 🔒 price-derived column needs a market-data feed.
Financials — annual
SEC EDGAR · last 5 FY| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $135,000 | $141,000 | $202,000 | $170,000 | $88,000 |
| Gross Profit | — | — | — | — | — |
| Operating Income | $-18.8M | $-19.9M | $-31.9M | $-19.8M | $-11.7M |
| Net Income | $-19.1M | $-19.4M | $-29.0M | $-17.3M | $-14.0M |
| Diluted EPS | $-0.40 | $-0.40 | $-0.60 | $-30.92 | $-8.62 |
| Operating Cash Flow | $-14.0M | $-16.1M | $-21.3M | $-14.9M | $-11.0M |
| Free Cash Flow | $-14.0M | $-16.2M | — | $-14.9M | — |
COMMUNITY · $AIM0 theses
POST YOUR TAKE →Fundamentals sourced from SEC EDGAR filings (public domain). For informational purposes only. Not investment advice.